Adam Brufsky to Breast Neoplasms
This is a "connection" page, showing publications Adam Brufsky has written about Breast Neoplasms.
Connection Strength
2.015
-
CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019 10; 20(10):1329-1330.
Score: 0.220
-
Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use? Breast J. 2019 01; 25(1):7-8.
Score: 0.210
-
Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast J. 2017 Nov; 23(6):718-722.
Score: 0.191
-
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017 Sep; 59:22-32.
Score: 0.189
-
TACT2: improving treatment tolerability in early breast cancer. Lancet Oncol. 2017 07; 18(7):843-845.
Score: 0.189
-
Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. Lancet Oncol. 2017 04; 18(4):428-429.
Score: 0.184
-
Is there room for bevacizumab in metastatic breast cancer? Lancet Oncol. 2016 09; 17(9):1175-6.
Score: 0.177
-
Pathologist's health-care value in the triage of Oncotype DX® testing: a value-based pathology study of tumour biology with outcomes. Histopathology. 2018 Oct; 73(4):692-700.
Score: 0.051
-
Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clin Breast Cancer. 2018 12; 18(6):e1239-e1245.
Score: 0.051
-
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018 09 01; 36(25):2621-2629.
Score: 0.051
-
Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? Am J Clin Pathol. 2018 May 31; 150(1):34-42.
Score: 0.050
-
Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer. Oncol Nurs Forum. 2018 05 01; 45(3):308-326.
Score: 0.050
-
Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. Am J Clin Pathol. 2018 Mar 07; 149(4):332-343.
Score: 0.050
-
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 02 01; 110(2).
Score: 0.049
-
Alcohol consumption and breast tumor gene expression. Breast Cancer Res. 2017 Sep 12; 19(1):108.
Score: 0.048
-
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017 08; 30(8):1078-1085.
Score: 0.047
-
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017 Aug 10; 35(23):2647-2655.
Score: 0.047
-
Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. Cancer. 2017 06 01; 123(11):2061-2069.
Score: 0.046
-
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. Cancer Med. 2017 02; 6(2):339-348.
Score: 0.046
-
Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015 Aug 01; 121(15):2627-36.
Score: 0.041
-
Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med. 2006 Oct; 130(10):1516-21.
Score: 0.022
-
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20.
Score: 0.007